← All trials
NCT05809414
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2022
- Primary completion
- Jul 15, 2024
- Completion date
- Feb 28, 2025
- First posted
- Apr 12, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 144
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Complutense de MadridLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- Universidad Complutense de MadridReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.